Diabetes gene at root of wider syndrome

“Gain of function” gene mutations associated with neonatal diabetes are now thought to be responsible for a range of other neurological dysfunctions.

PRESS RELEASE FROM EUROPEAN JOURNAL OF HUMAN GENETICS
(http://www.nature.com/ejhg/index.html)

This press release is copyrighted to European Journal of Human Genetics. Its use is granted only for journalists and news media receiving it directly from the Nature Publishing Group.

Diabetes gene at root of wider syndrome

European Journal of Human Genetics advance online publication, 03 May 2006;
DOI: 10.1038/sj.ejhg.5201629

“Gain of function” gene mutations associated with neonatal diabetes are now thought to be responsible for a range of other neurological dysfunctions. These mutations of the KCNJ11 gene are involved in up to 50% of neonatal diabetes, and research published online this week by the European Journal of Human Genetics shows these same mutations to cause a syndrome that can include developmental delay, epilepsy and muscle weakness.

In the study, Anna Gloyn and colleagues present a novel mutation, C166F, in the gene KCNJ11. They show that this and two other known KCNJ11 mutations involved in diabetes also lead to different features of the syndrome known as Developmental delay, Epilepsy and Neonatal Diabetes (DEND).

The researchers believe that as the gene is expressed in different tissues and muscles the mutation results in neurological features that are separate and distinct from features resulting directly from acute or chronic diabetes. To date only three patients have been identified with a KCNJ11 mutation as well as developmental delay and epilepsy; the patient with the novel C166F mutation in this study, resulting in full DEND, is the fourth, and supports the thesis that this particular clustering of features is due to these mutations.

Neonatal diabetes occurs once every 400,000 births and can be either transient or permanent. Little is known about it, particularly on its long-term course. Members of the research team hope to perform genetic screening on patients who were diagnosed with diabetes before six months of age to help determine treatment.

Author contact:
Dr Anna L Gloyn (Churchill Hospital, Oxford, UK)
Tel: +44 1865 857343; Email: [email protected]

Editorial contact:
Sarah Cheung (Assistant Editor - Academic Journals, Nature Publishing Group, London, UK)
Tel: +44 20 7843 4857; E-mail: [email protected]

AN EMBARGOED PDF COPY OF THIS PAPER IS NOW AVAILABLE ON THE ACADEMIC JOURNALS SECTION OF THE PRESS SITE
http://press.nature.com

Nature Publishing Group (NPG) is a division of Macmillan Publishers Ltd, dedicated to serving the academic, professional scientific and medical communities. NPG's flagship title, Nature, is the world's most highly-cited weekly multidisciplinary journal and was first published in 1869. Other publications and services include Nature research journals, Nature Reviews, Nature Clinical Practice, a range of prestigious academic journals, including society-owned publications, news content from [email protected] and scientific career information from Naturejobs.

NPG is a global company, with headquarters in London and offices in New York, San Francisco, Washington DC, Boston, Tokyo, Paris, Munich, Hong Kong, Melbourne, Gurgaon, Mexico City and Basingstoke. For more information, please go to www.nature.com <http://www.nature.com>.

Published: 03 May 2006

Contact details:

The Macmillan Building, 4 Crinan Street
London
N1 9XW
United Kingdom

+44 20 7833 4000
Country: 
News topics: 
Content type: 
Reference: 

EUROPEAN JOURNAL OF HUMAN GENETICS